Last updated: December 13, 2013
Sponsor: UCB Pharma
Overall Status: Completed
Phase
3
Condition
Allergy
Common Cold
Nasal Obstruction
Treatment
N/AClinical Study ID
NCT00544388
A00379
Ages > 16 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Male/Female, aged >= 16 years
seasonal allergic rhinitis that required pharmacologic therapy each year during thelast 2 ragweed pollen seasons
documented seasonal allergy to ragweed pollen
total symptom score of at least 18 points.
Exclusion
Exclusion Criteria:
nasal anatomic deformities ? 50% obstruction
acute sinusitis within 30 days of Period 2
initiated or advanced an immunotherapy regimen
immunotherapy injections within 48 hours of pollen exposure
impaired hepatic function
history of malignancy
intolerance to histamines
asthma requiring medication more than occasionally
Study Design
Total Participants: 570
Study Start date:
April 01, 2004
Estimated Completion Date:
July 31, 2004